This is an aggregated industry headline. Read the full story at FierceBiotech →
Insilico's Chinese partner returns for $177M pact to explore 'mass market' CNS indication
Pharma platform company China Medical System Holdings has tapped up existing partner Insilico for a 1.2 billion yuan ($177 million) collaboration aimed at a "mass-market" central nervous system indication.
By FierceBiotech
· Jul 13, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The three-part video podcast series features Londyn, 15, and Connor, 20, who live with phenylketonuria, or PKU…
The WeekBriefing
Apnimed is preparing a potential IPO to finance the commercial rollout of its obstructive sleep apnea therapy,…
The WeekPharmaceutical Technology ↗
The FDA has approved two of MSD's anti-PD-1 therapies, Keytruda and Keytruda Qlex, along with Padcev, for adul…